At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 36 enrolled
Drug / intervention
Ustekinumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI)
In Brief
A Phase 4 clinical trial evaluating Ustekinumab for Psoriasis. Completed, enrolled 36 participants across 1 site.
Detailed Summary
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartMar 2012
Primary CompletionDec 2014
TodayJul 2026
First PostedJan 18, 2012
Enrollment StartMar 1, 2012
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.5 years ago
Interventions
Ustekinumabdrug
Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.